Dual T1/ T2 Nanoscale Coordination Polymers as Novel Contrast Agents for MRI : A Preclinical Study for Brain Tumor by Suárez García, Salvio et al.
This document is the Accepted Manuscript version of a Published
Work that appeared in final form in ACS Applied Materials and
Interfaces, copyright © American Chemical Society after peer
review and technical editing by the publisher. To access the final
edited and published work see:
https://dx.doi.org/10.1021/acsami.8b15594.
 1 
Dual T1/T2 Nanoscale Coordination Polymers as 
Novel Contrast Agents for MRI: a Preclinical Study 
for Brain Tumor    
S. Suárez-García,
†
  N. Arias-Ramos,
§,‡
 C. Frias,
† 
A. Paula Candiota,
‡,
 
§,$
  C. Arús,
§,‡,$
 J. 
Lorenzo,
§,$,
* D. Ruiz-Molina,
†
  F. Novio
†,#,
** 
 
† Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 
Barcelona, Spain.  
§ Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del 
Vallès, Spain. 
‡ Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina, 08193 Cerdanyola del 
Vallès, Spain. 
$ Institut de Biotecnologia i de Biomedicina. Departament de Bioquimica i Biologia Molecular. Universitat 
Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain. 
# Departament de Química, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain. 
* Dr Julia Lorenzo.  Ph: +(34) 935868936 Fax: +(34) 935812011.  E-mail: julia.lorenzo@uab.cat 
** Dr Fernando Novio. Ph: +(34) 937373630 Fax: +(34) 937372648.  E-mail: fernando.novio@icn2.cat 
KEYWORDS  
Nanoparticles, Coordination Polymers, Contrast agents, Dual imaging, MRI, Nanomedicine. 
 2 
ABSTRACT 
In the last years, extensive attention has been paid on designing and developing functional 
imaging contrast agents for providing accurate non-invasive evaluation of pathology in vivo. 
However, the issue of false-positives or ambiguous imaging and the lack of a robust strategy for 
simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for 
improving it is to rationally design magnetic resonance imaging (MRI) contrast agents (CAs) 
with intrinsic T1/T2 dual-mode imaging features. In this work, the development and 
characterization of one-pot synthesized nanostructured coordination polymers (NCPs) which 
exhibit dual mode T1/T2 MRI contrast behaviour is described. The resulting material comprises 
the combination of different paramagnetic ions (Fe
3+
, Gd
3+
, Mn
2+
) with selected organic ligands 
able to induce the polymerization process and nanostructure stabilization. Among them, the Fe-
based NCPs showed the best features in terms of colloidal stability, low toxicity, and dual T1/T2 
MRI contrast performance overcoming the main drawbacks of reported CAs. The dual-mode CA 
capability was evaluated by different means: in vitro phantoms, ex vivo and in vivo MRI, using a 
preclinical model of murine glioblastoma.  Surprisingly, the in vivo MRI shows its T1 and T2 high 
contrast potential, allowing simultaneous recording of positive and negative contrast images in a 
very short period of time while being safer for the body. Moreover, the biodistribution assays 
reveals the persistence of the nanoparticles in the tumor and subsequent gradual clearance 
denoting their biodegradability. After a comparative study with commercial CAs, the results 
suggest these nanoplatforms as promising candidates for the development of dual-mode MRI 
CAs with clear advantages. 
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1. Introduction 
Magnetic resonance imaging (MRI) is a powerful technique for gathering tomographic images 
of biological soft tissues in a non-invasive manner with a high spatial resolution and depth 
penetration. This radiation-free technique enables the coding of nuclear magnetization into 
2D/3D images, being the most used tool in clinical diagnosis. The signal intensity of proton-
based MRI (
1
H-MRI) depends on a combination of factors: proton density, longitudinal (T1) and 
transversal (T2) relaxivity times and the cell microenvironment.
1,2
 However, the intrinsic contrast 
provided by the combination of these factors and the biological changes due to a disease are not 
enough for obtaining accurate and sensitive diagnosis. For these reasons, the use of contrast 
agents (CAs) in MRI diagnosis is needed in order to improve image resolution due to their 
selective accumulation in the Region-Of-Interest (ROI). CAs can shorten longitudinal and 
transverse relaxation of protons respectively causing a positive enhancement (i.e. brighter image) 
in T1-weighted (T1w) MRI and negative enhancement (i.e. darker image) in T2-weighted (T2w) 
MRI in comparison with pre-contrast images.
3,4,5
 Unfortunately, most of the T1 and T2 CAs 
clinically approved for MRI diagnosis, have associated several disadvantages. Usually, T1 CAs 
are based on chelating complexes of paramagnetic gadolinium.
6
 The presence of Gd
3+
 has been 
related with some technical issues and health risks such as headache, nausea, dizziness and 
severe nephrogenic system fibrosis (NSF).
7,8,9,10,11
 Furthermore, long-term deposition of Gd in 
the human brain due to their incomplete clearance from the organism, has been recently 
reported.
12,13
 Apart from Gd, manganese (II) has been presented as alternative CA for T1w 
images. However, the accumulative toxicity arising from Mn
2+
 which induces neurological 
degeneration or oxidative stress in cells, might limit its clinical application. On the other hand, 
typical contrast agents in T2W images are generally based on superparamagnetic iron oxide 
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nanoparticles or ferrites (e.g. SPIONs).
14,15
 Nevertheless, the analysis process of resulting T2w 
images are laborious due to the low signal body regions that can be confused with hemorrhages, 
calcifications, fat, blood clots and other possible artefacts in damaged tissue.
16
 Although most of 
the recent developments are based on inorganic nanoparticles,
17
 in the last years hybrid metal-
organic
18
 and metal-free organic
19 
nanoparticles has been proposed as good CAs for MRI due to 
their minimal cytotoxicity and biodegradability in comparison to metal-based contrast agents. 
At this point, and in spite of extensive research has been carried out to obtain novel MRI CAs, 
the single mode contrast agents are far from being optimum. Current CAs exhibit major 
limitations in terms of MRI artefacts, imaging ambiguities and health risks. In order to overcome 
these limitations, a great effort has been done in the combination of techniques in order to 
stablish dual-imaging procedures (e.g. PET/MRI). Nevertheless, due the confounding results and 
the difficult of clinical implementation of the dual-imaging techniques, only a few of them have 
earned admittance to clinical applications. For this reason, dual-modal MRI has demonstrated 
enough merits and good perspectives in practical diagnosis to avoid such limitations by simply 
adjusting the acquisition sequences.
20
 Furthermore, T1/T2 dual-mode MRI is performed by single 
scanner, ensuring a perfect match of spatial and temporal imaging parameters being more 
beneficial compared to other bimodal imaging techniques.
21,22
 
In this scenario, the development of novel T1/T2 dual-mode contrast agents (DMCAs) with 
clinical proof of their in vivo performance is a pressing concern. DMCAs can be selectively 
tuned to visualize by bright or dark T1w and T2w images in order to obtain complementary and 
more precise information by cross-validation of the possible false-positives.
23
 The synthesis of 
T1/T2 DMCAs in a single platform is currently a challenge. In this sense, different strategies 
based on nanoscale engineering have been developed during the last years. These strategies 
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consisted mainly in i) direct conjugation of T1 compounds (e.g., Gd or Mn-containing systems) 
and T2 compounds (e.g., SPIONs).
21,24-26
 (ii) T2 materials doped with T1 contrast materials;
19,27-29 
(iii) magnetic nanoparticles with rational modulation of size and magnetization;
3,30
 and (iv) 
integration of T1 contrast materials with nonmagnetic porous materials.
31-34
 However, these 
strategies are often involved in laborious procedures with multi-step synthesis. Furthermore, the 
possibility of quenching effect between T1 and T2 due to the interaction between both relaxation 
times requires a delicate control limiting their production and clinical applications.
23
  
Based on this rationale, nanoscale coordination polymers (NCPs) have appeared during the last 
years as good candidates for their use in medical applications. The interest of NCPs lies in their 
rational chemical design based on multiple combinations between metal ions and polydentate 
ligands. The potential multifunctionality of these nanosystems implies longer blood circulation 
times as compared to common chelates, less metal leaching and greater area between 
magnetically centers and the tissue due to the increased surface-to-volume ratio. Encouragingly, 
previous studies showed that biodegradable NCPs could provide T1w properties and be combined 
with T2w contrast agents to obtain nanosystems with dual-mode MRI properties.
35
 Different 
approaches have been reported recently in order to synthesize DMCAs by Eu co-doping of a Gd 
NCP complex,
36
 the use of porphyrin ligands for the chelation of Fe,
37
 or polydopamine-based 
coordination complex and its affinity for Fe ions.
33
 
Despite the progress of DMCAs, some questions remain need to be addressed before the 
clinical application of DMCAs become a reality: i) facile synthesis procedures with possibilities 
for scale up, ii) chemically stable in biological environment by non- toxicity and non-
accumulation in the organism (avoiding the use of Gd and Mn ions) and iii) high efficiency in 
different tissues by good biodistribution (low uptake in liver and kidneys).
38
 These key 
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parameters have to be considered during the rational design of novel DMCAs overcoming the 
main drawbacks of current clinical approved CAs.  
Therefore, there is still need to overcome the disadvantages of single modality CAs by the 
preparation of robust DMCAs which are supposed to minimize the risks of ambiguity and 
improve the diagnostic sensitivity. Herein we demonstrate the intrinsic ability of NCPs 
complexes based on paramagnetic ions (Fe
3+
, Gd
3+
, Mn
2+
) to generate in a facile, robust and 
reproducible one-pot synthesis biodegradable DMCAs nanoparticles. In a deeper study, we 
selected the Fe-based NCPs (Fe-NCP) nanosystem as a suitable candidate for preclinical studies, 
which overcomes the main issues of contrast agents:  i) cheap one-pot procedure, ii) chemically 
stable, iii) non-toxic and biocompatible, iv) intrinsically T1 and T2 imaging capabilities in vitro 
and in vivo and v) good biodistribution with low uptake by liver and kidneys. This rational 
design provides a protocol for the synthesis of novel systems in successful way, which reduces 
the main limitations of other reported systems.  To the best of our knowledge, this is the first 
report on the fabrication of Fe-NCP for T1w/T2w contrast enhancement for the diagnosis and 
visualization of glioblastoma in vivo allowing the imaging of cerebral lesions. Our work would 
help to the development of novel one-pot NCP-based DMCA systems as a valid strategy with 
potential applications in theranostic and clinical translation to T1/T2 dual-mode MRI.  
2. Experimental section 
2.1 Materials. Solvents and starting materials were purchased from Sigma–Aldrich 
(Merck, Madrid, Spain) and used as received, without further purification, unless 
otherwise stated. 1,4-Bis(imidazol-1-ylmethyl)benzene (L1, Bix) was synthesized 
according to previously reported methodology.
39
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2.2 Characterization. Scanning electron microscopy (SEM) was performed for platinum-
metallized samples on a FEI Quanta 650 FEG (Thermo Fisher Scientific, Eindhoven, The 
Netherlands) in mode operation of secondary electrons (SE) with a beam voltage between 
5 and 20 kV. Fourier-transform infrared spectra (FT-IR) were recorded on a Tensor 27 
FT-IR spectrometer (Bruker Optik GmbH, Berlin, Germany) with KBr pellets. 
Ultraviolet-visible spectroscopy (UV-Vis) was performed using a Cary 4000 UV-vis 
spectrometer (Agilent Technologies, Santa Clara, CA, USA) within range wavelengths 
from 200 to 800 nm and a 1 cm path length quartz cuvette (QS 10 mm). The baseline was 
corrected using a blank sample of pure solvent. All the measurements were taken under 
atmosphere conditions. Dynamic light scattering (DLS) measurements for obtaining size 
distribution and zeta potential (ζ-potential) of the nanostructures were performed using a 
Zetasizer Nano ZS 3600 (Malvern Instruments, U.K.). All analyzed samples were diluted 
in order to obtain a concentration of nanoparticles suitable for the experimental 
calculation of size dispersion. The data reported are values coming from the mean of 
measurements for each sample which were measured per quadruplicate. Inductive 
coupled plasma-mass spectroscopy measurements (ICP-MS) were obtained using an ICP-
MS NexION 300X (Perkin Elmer, San Francisco, CA, USA). All samples were measured 
in argon atmosphere. X-ray photoelectron spectroscopy (XPS) measurements were 
performed with a Phoibos 150 analyzer (SPECS GmbH, Berlin, Germany) in ultra-high 
vacuum conditions (based pressure 10
-10
 mbar). Monochromatic Al Kα was used as X-ray 
source (1486.6 eV). The electron energy analyzer was operated with pass energy of 50 
eV. The analyzer was located perpendicular to the sample surface. The data was collected 
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every eV with a dwell time of 0.5 s and treated with CasaXPS version 2.317PR1.1 /Casa 
Software LTD, Teignmouth, UK). 
2.3 Synthesis of Fe-NCP, Gd-NCP and Mn-NCP. 1,4-Bis(imidazole-1-ylmethil)-benzene (L1, 
Bix – 60 mg, 0.25 mmol) and 3,4-dihydroxycinnamic acid (L2, dhc – 90 mg, 0.5 mmol) were 
dissolved in 15 mL of ethanol under vigorous and homogenous magnetic stirring (700 rpm) 
during 30 minutes at room temperature. Subsequently, the solution was treated with an aqueous 
solution containing metal salt either Fe(CH3COO)2 (43.5 mg, 0.25 mmol in 2 mL H2O; for Fe-
NCP), Gd(CH3COO)3·6H2O (83 mg, 0.25 mmol in 2 mL H2O; for Gd-NCP) or Mn(CH3COO)2 
(61 mg, 0.25 mmol in 2 mL H2O; for Mn-NCP), which turned the solution either black-purple, 
yellow and dark green, respectively, and led to rapid formation of a precipitate.  
Fe-NCP: IR (KBr): 3140 (w, δ (C–Hring)), 2974 (w), 1678 (w), 1623 (s, ν(C=N)), 1575 (w), 
1519 (s, ν(C–Hring)), 1481 (s, ν(C–O)), 1398 (s), 1263 (s, ν(C–O)),  1105 (m), 980 (m), 864 (s,  
δ(N-Hring)), 521 (s, Fe–O) cm
−1
. Anal. Calcd (%) for Fe-NCP: C 47.03, H 4.58, N 5.86; found: C 
47.00, H 3.82, N 5.92. ICP-MS Calcd (%) for Fe-NCP: Fe 12.05; found: Fe 11.85. 
Compositional formula: Fe1L10.49L21.30(AcO
-
)0.25(H2O)3.82. 
Gd-NCP: IR (KBr): 2926 (w, δ (C–Hring)), 2853 (w, ν(C–Haliphatic)), 1631 (s, ν(C=N)), 1520 (w, 
νC–Hring)), 1416 (s, ν(C–O)), 1271 (s, ν(C–O)),  1121 (m), 978 (m), 864 (s,  δ(N–Hring)), 542 (s, 
Gd–O)  cm−1. Anal. Calcd (%) for Gd-NCP: C 38.79, H 4.06, N 5.89; found: C 38.00, H 3.20, N 
6.08. ICP-MS Calcd (%) for Gd-NCP: Gd 29.50; found: Gd 29.90. Compositional formula: 
Gd1L10.57L21.03(AcO
-
)0.30(H2O)3.11. 
Mn-NCP: IR (KBr): 3128 (w, δ (C–Hring)), 2972 (w),  2934 (w, ν(C–Haliphatic)), 1629 (s, 
ν(C=N)), 1520 (w, νC–Hring)), 1489 (s, ν(C–O)), 1261 (s, ν(C–O)),  1110 (m), 859 (s,  δ(N–Hring), 
558 (s, Mn–O) cm-1.  Anal. Calcd (%) for Mn-NCP: C 53.07, H 5.19, N 8.44; found: C 52.40, H 
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4.10, N 8.26. ICP-MS Calcd (%) for Mn-NCP: Mn 7.74; found: Mn 7.67. Compositional 
formula: Mn1L11.07L21.82(AcO
-
)0.28(H2O)3.09. 
2.4 Synthesis of GdDTPA-NCP. 1,4-Bis(imidazole-1-ylmethil)-benzene (L1, Bix – 60 mg, 0.25 
mmol) and diethylenetriaminepentaacetic acid (L3, DTPA – 84 mg, 0.25 mmol) were dissolved 
in 15 mL of ethanol under vigorous and homogenous magnetic stirring (700 rpm). Subsequently, 
the solution was treated with and aqueous solution containing metal salt Gd(CH3COO)3·6H2O 
(Gadolinium (III) acetate - 83 mg, 0.25 mmol in 2 mL H2O), which turned the solution deep 
yellow and led to rapid formation of a precipitate.  
GdDTPA-NCP: IR (KBr): 2980 (w, δ (C–Hring)), 1678 (w, ν(C=N)), 1598 (w, νC–Hring)), 1411 
(s, ν(C–O)), 1266 (s, ν(C–O)), 1118 (m), 931 (m), 866 (s,  δ(N–Hring), 549 (s, Gd–O) cm
-1
.  Anal. 
Calcd (%) for GdDTPA-NCP: C 46.75, H 4.87, N 13.92; found: C 46.89, H 4.70, N 14.45. ICP-
MS Calcd (%) for GdDTPA-NCP: Gd 20.07; found: Gd 20.50. Compositional formula: 
Gd1L11.39L30.70(H2O)1.2. 
All the synthesis reactions were carried out during 30 minutes under room temperature and at 
atmospheric conditions. The obtained precipitates were centrifuged (7500 rpm, 5 min) and 
washed with water and ethanol. The precipitates were vacuum dried and the solvent was 
removed. 
2.5 Functionalization of NCPs with BSA. All the systems synthesized were functionalized with 
Bovine or Mouse Serum Albumin (BSA or MSA, respectively) in order to obtain better 
dispersions reducing the formation of aggregates in solution. All the solutions were prepared in a 
phosphate buffer (PBS, pH = 7.4) with a physiological concentration of BSA (0.5 mM). The 
nanoparticles were added to the solution containing BSA and PBS under magnetic stirring at 37 
o
C during 1h. 
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2.6 In vitro assays 
2.6.1. Quantitative magnetic resonance imaging phantoms (MRI-Phantoms). The samples 
of nanoparticles were dispersed using agarose (1%) in phosphate buffer solution (PBS) at pH = 
7.4. For all families of nanostructures, five samples at decreasing concentrations (0.6, 0.3, 0.1, 
0.05 and 0 mM of metal mL
-1
) were prepared in 1.5 mL Eppendorf tubes. The total volume was 
adjusted up to 1 mL with agarose in PBS. The dispersions were well dispersed in an ultrasound 
bath just before the solidification of medium. Acquisition sequences for assessing longitudinal 
relaxation (T1) and transversal relaxation (T1) were carried out with 7T (300 MHz) Bruker 
BioSpec 70/30 USR spectrometer (Bruker BioSpin GmbH, Ettlingen, Germany).  
2.6.2. Cell culture. Human cervical carcinoma cells (HeLa) were used to test the toxicity of 
the different nanostructures synthesized and the commercial CAs. The cell line was obtained 
from the American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in 
MEM Alpha medium (Invitrogen) supplemented with 10% (v/v) heat inactivated fetal bovine 
serum (FBS) and incubating them at 37 
o
C under atmosphere with 95% humidity and 5% CO2.   
2.6.3. Cell viability studies. HeLa cells in logarithmic growth phase were seeded by adding 
3000 cells/well in 100 µL final volumes in 96-well microplates. After 24 h, cells were treated 
with increasing doses of the NCPs or commercial CAs based on Gd (Gadopentetate 
dimeglumine, GdDTPA, Guerbet, Roissy, France) and Mn (Mangafodipir trisodium, MnDPDP, 
Bayer Healthcare). The effect on cell viability after 24h and 72h was determined using the 
PrestoBlue reagent assay, which is based on the metabolic reduction of resazurin on resorufin. A 
Victor3 (Perkin Elmer) fluorimeter plate reader was used to obtain the measurements by 
fluorescence reading directly from 96-well microplates at an excitation wavelength of 531 nm 
and emission wavelength of 572 nm. The percentage of cell viability was calculated by dividing 
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the absorbance of each well by the corresponding value of the control wells (cells without 
treatment). The cytotoxicity studies were carried out by triplicate and a minimum of four 
independent experiments performed on different days. The data was treated with GraphPad 
Prism software (Version 4.0).  
2.6.4. Intracellular reactive oxygen species (ROS) generation studies. Measurement of 
intracellular ROS activity was based on fluorescence emission measurements using CellRox 
Green Reagent (Molecular Probes). HeLa cells were seeded in 96-well microplates allowed to 
attach and grow during 24 h. After this time, cells were treated 24 h more with NCPs or 
commercial CAs. Finally, 20 µL of CellRox reagent was added to each well and incubated for 30 
min. Two controls were made: one with cells treated only with cell culture medium as a 
reference value, and second with H2O2 (as an oxidative stress inducer for positive control). The 
measurements were recorded at an excitation wavelength of 485 nm and emission wavelength of 
535 nm using a Victor3 (Perkin Elmer) fluorimeter. 
2.7. Ex vivo/In vivo assays 
2.7.1. Animal models. Animal studies were approved by the local ethics committee, according 
to the regional and state legislation (protocol DMAH-8333/CEEAH-2785). C57BL/6J female 
mice of 12 weeks of age, weighting 21.4 ± 1.2 g (n = 12) were purchased from Charles River 
Laboratories (l’Abresle, France) and housed in the animal facility of the Universitat Autònoma 
de Barcelona. For ex vivo studies, control C57BL/6J mice were used. For in vivo studies, GL261 
tumor-bearing mice were used, except for tolerability evaluation. 
2.7.2. MRI Studies. All MRI studies were performed at the joint nuclear magnetic resonance 
facility of the Universitat Autònoma de Barcelona and Centro de Investigación  Biomédica en 
Red – Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) (Cerdanyola del Vallès, 
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Spain), Unit 25 of NANBIOSIS, www.nanbiosis.es. The 7T Bruker BioSpec 70/30 USR 
spectrometer (Bruker) equipped with a mini-imaging gradient set (400 mT/m) was used for MR 
acquisitions.   
2.7.3. MRI ex vivo studies. The CAs were dispersed in 2 ml PBS added with 0.5 mM BSA. 
The final amount used for each animal was 5 nmol of metal dissolved in 4 μl PBS - BSA 
solution. Commercial solutions of CAs based on Gd (GdDTPA) and Mn (MnDPDP) were used 
as standards to compare the enhancement obtained with the NCPs synthesized. Three injection 
points were used in each mouse (n = 2 for each CA). High resolution T1w and T2w MR images 
(TR/TE =4200/12 ms) were acquired using a rapid acquisition with relaxation enhancement 
(RARE) sequence for a morphological characterization of the investigated tissue. All the CAs 
administrations were done post mortem using a stereotactic holder. 
2.7.4. Tolerability Studies. Increasing amounts of Fe-NCP (0.03 to 0.4 mmol Fe Kg
-1
) were 
intravenously (i.v.) administered to n = 3 mice with a 2-day rest period between injections. An 
additional group of n = 3 wild type (wt) mice was injected with the vehicle for in vivo studies 
(PBS + 0.5 mM of MSA).  Mice body weight and other welfare parameters were followed up for 
detection of any signs of animal suffering during 30 days after the last administration. No higher 
doses were tested in this assay.  
2.7.5. MRI in vivo studies. GL261 tumor-bearing mice (n = 3, 12.7 ± 0.6 days after tumor 
implantation, tumor volume 38.1 ± 27.5 mm
3
) were placed in a mouse bed and anesthetized with 
isoflurane 0.5–1.5% in O2. Breathing (60-80 breaths/min) and temperature (37-38 °C) were 
constantly monitored (SA Instruments, Inc., New York, USA).  A first experiment with 
commercial GdDTPA administration was carried out. A second experiment with Fe-NCP was 
performed with n = 3 mice. The amount of CA injected in tumor-bearing mice was 107.1 ± 6.4 
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µl (0.4 mmol metal kg
-1
). In order to assess both T1 and T2 RCE, T1w and T2w images (TR/TE = 
200/8.5 ms and 4200/12 ms, respectively) were acquired before and immediately after i.v. 
injection of CA. Three T1w and three T2w images were acquired before the CA injection. Then, 
alternated T1w – T2w images were acquired continuously during 30 min after CA administration, 
resulting in a total of 15 frames for T1w and 15 frames for T2w images. In addition, individual T1w 
and T2w acquisitions were also performed at 2 and 24 h after CA administration. Studies were 
also conducted (n = 3) with the vehicle of administration (PBS-MSA) with a standard DCE-MRI 
sequence consisting in T1w MRI acquisitions in a total of 70 frames, with no T2 alternating 
sequences.  
2.7.6. Processing and post-processing of MR data. For ex vivo studies, ROIs were selected 
in T1w and T2w images, corresponding to the CAs administration points. They were manually 
defined after visual inspection in the area of maximum enhancement and an equivalent area of 
contralateral parenchyma. The relative contrast enhancement (RCE) - injection site ROI vs. 
contralateral parenchyma - obtained in each case was used for calculations (see Equation 1). 
Only the slice with better defined contrast-enhanced region in the best study was used for 
measurements. For dual enhancement images, T1w and T2w images were processed with the 
algebra algorithm (MR signal T1 /MR signal T2) provided by Paravision 5.1.   
                       RCE(%)𝑒𝑥 𝑣𝑖𝑣𝑜 = (
𝑆(𝑖)
𝑆(𝑐)
)  x 100           (Equation 1) 
Where S(i) is the absolute signal intensity of the “ipsilateral” region with respect to the 
contrast administration (visually shows contrast enhancement) and S(c) is the absolute signal 
intensity of the equivalent contralateral region.  
For in vivo studies, two ROIs were manually selected in each slice: one corresponding to the 
tumor area and the second corresponding to contralateral normal brain tissue. Then, RCE for 
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each slice was calculated as in ex vivo studies. Mean RCE of the three images acquired before 
CA injection was referred as 100%, and then RCE signals of images acquired after CA injection 
were estimated accordingly.  
2.8. Statistical analysis. Normality of the distribution values was inspected with Kolmogorov-
Smirnov test. Variance equality was estimated with Levene’s test. Student’s t-test was used for 
RCE bilateral comparisons. The in vitro, ex vivo and in vivo RCE evolution during the first 30 
minutes was performed with UNIANOVA. Significance level was set to 0.05. 
2.9. Biodistribution studies. ICP-MS was used for the biodistribution of Fe-NCP. For each 
experimental group, prior to injection, a nanoparticle aliquot was saved for the determination of 
iron concentration in the injected material. After the in vivo experiments, the mice were 
euthanized and the organs of interest (brain, tumor, lungs, bladder, kidneys and liver) excised 
and stored at -80 ºC. Previous to ICP-MS measurements, organ samples were thoroughly washed 
with PBS and blotted dry to minimize the contribution of any nanoparticles still circulating in the 
blood. The organs were weighted into vials and digested overnight at 70 ºC with 1 ml of protein 
extraction reagent (T-PER™, Thermo Fisher Scientific) per 100 mg of tissue and 10 mL of aqua 
regia (1HNO3:3HCl, trace metal grade) (v/v). After that, the organs were sonicated with an 
ultrasounds probe (Branson 550, Emerson, St Louis, MO, USA) for 10 cycles until the complete 
digestion (300 W, 10 min). For the quantification of metal a dilution 1:100 was necessary for 
detecting the correct signals. For ICP-MS analysis, atomic spectroscopic analytical standards 
were purchased from PerkinElmer Pure Plus. The isotope 
57
Fe was selected as tracer. The iron 
concentration of each sample was measured using a calibration curve obtained in the range of 
0.01-500 ppb of metal. Standard reference material (PerkinElmer) with known values of Iron 
was analyzed with each batch of samples. All the samples were measured per quadruplicate. For 
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protein quantification a Bradford kit protocol was used (Quick Start Bradford Dye reagent X1, 
Biorad, Hercules, CA, USA). The biodistribution of iron ions was plotted per µg of protein 
content in each organ. The results were expressed as mean ± SD. An unpaired Student’s t-test 
was used. Significant level was set to 0.05. 
3. Results and Discussion 
3.1 Synthesis and characterization of NCPs 
The synthesis of NCPs containing three different paramagnetic ions widely used as CAs for 
MRI (Fe
3+
, Gd
3+
 and Mn
2+
) was achieved. The NCPs where synthesized using a previously 
published methodology
40
 through the reaction of Fe(CH3COO)2, Gd(CH3COO)3·6H2O or 
Mn(CH3COO)3 metal salts with 1,4-Bis(imidazole-1-ylmethil)-benzene (L1, Bix) and 3,4-
dihydroxycinnamic acid (L2, dhc) as a co-ligand in a 1:1:2 molar ratio, and using EtOH as 
solvent. These reactions afforded the formation of the nanoparticles named Fe-NCP, Gd-NCP 
and Mn-NCP, respectively. Alternatively, the polymerization of the well-known commercial CA 
for MRI based on Gd (Gadopentetate dimeglumine, GdDTPA) was tested in similar way by 
mixing Gd(CH3COO)3·6H2O with L1 and diethylenetriaminepentaacetic acid (L3, DTPA) as a 
co-ligand (Figure 1a). In a first trial, the idea was to polymerize the commercial GdDTPA 
chelate using different ligands. However, all the attempts to obtain this coordination polymer 
were unsuccessful. For this reason, the formation of the chelate and subsequent polymerization 
process was performed in situ as detailed in the Experimental section. In the same way, 
polymerization of the Manganese-based commercial CA (Mangafopidir trisodium, MnDPDP) 
was attempted. Nevertheless, the resulting polymer showed low reproducibility and low 
chemical stability in aqueous solution and, for this reason, the system was discarded. 
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All the NCPs were characterized by SEM, showing different diameter size ranging from 45 ± 5 
nm (Fe-NCP) to 130 ± 7 nm (Mn-NCP) (Figure 1b-e and Table 1). In solution, DLS 
measurements in PBS buffer show higher hydrodynamic diameters in comparison with SEM 
measurements. In general, good monodispersion values (PDI < 0.20) and colloidal stability are 
found for all samples, except for the Mn-based NCP (Mn-NCP), which start to aggregate in a 
relatively short time (sedimentation observed after 1 h). This aggregation process can be related 
to the surface charge or the low chemical stability of the nanoparticles. Indeed, the ξ-potential 
measurements show strong negative values for Iron and Gadolinium-based NCPs (-31.2 and -
27.2 mV, respectively). Otherwise, Mn-NCP shows weaker ξ-potential values (-15.4 mV) 
inducing low electrical repulsion between the nanoparticles (Table 1). With the aim to mimic the 
physiological environment and improve the colloidal stability of the NCPs, the nanoparticles 
were dispersed in a solution containing PBS and BSA (0.5 mM) at physiological conditions.
41,42
 
The results obtained demonstrate an improvement on the dispersions and colloidal stability of the 
NCPs in aqueous media, reducing the visible aggregation and showing hydrodynamic diameters 
close to the mean size values obtained by SEM (see Table 1 and Figure S1a-b). 
The chemical characterization of the resulting nanoparticles was performed by different 
complementary techniques. The FT-IR spectroscopy for Fe/Gd/Mn-NCPs shows the 
disappearance of the bands corresponding to the catechol –OH groups of L2 in the range of ν = 
3000-3500 cm
-1
, reflecting their deprotonation. Moreover, the vibration band assigned to a C–O 
stretch for the catechol coordinated to the metal appears in the frequency range 1400-1420 cm
-1
. 
The prevalence of carboxylic acid groups is confirmed by the presence of the characteristics 
vibrational bands of C=O and C–OH in the range ν = 1650-1580 cm-1 and 1250-1200 cm-1, 
respectively. Additionally, typical vibrational bands of L1 (ν = 1520, 1232, 1105 cm-1) are 
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observed in the IR spectra (Figure S2a-d). In the specific case of GdDTPA-NCP, the 
coordination of the carboxylic groups to Gd
3+
 ions, is confirmed by the presence of the 
characteristics vibrational bands of the COO
–
 carboxylate group at ν = 1590 cm-1 and ν = 1380 
cm
-1
.    
The FT-IR spectra comparison between GdDTPA-NCP complex and the Gd commercial CA 
(GdDTPA), reflects a good agreement on GdDTPA related signals and the presence of the 
additional peaks corresponding to the Bix (L1) ligand used as linker between metal centers 
(Figure S2d). The XPS measurements, confirm the presence and oxidation state of the metals 
being Fe(III), Gd(III) and Mn(II) in each case (Figure S3a-e). Additionally, Mössbauer 
spectroscopy confirms that Fe-NCP show a high-spin Fe(III) oxidation state (Figure S4). The 
chemical compositional formula of different complexes was experimentally calculated by 
combination of 
1
H-NMR, ICP-MS and elemental analysis. The ligand ratio of NCPs was 
obtained from 
1
H-NMR and the metal percentage from ICP-MS (Table S1-S2). These results 
together with the elemental analysis of C, N and H, help to elucidate an average compositional 
formula (the experimental compositional formulas for each NPC complex are shown in the 
Experimental section). As the NCPs are obtained out of equilibrium, it is worth mentioning that 
elemental analysis of different nanoparticles batches slightly differ from the expected values for 
a 1(metal ion):1L1:2L2 (or L3) ratio. These differences have been tentatively attributed to the 
plausible encapsulation of free ligand or solvent molecules within the particles and the formation 
of secondary structures such as oligomers.
43,44
 Finally, the absence of diffraction peaks observed 
by powder X-ray diffraction (PXRD) indicates the amorphous nature of all the samples. (Figure 
S5) 
3.2 Biodegradability of NCPs 
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The size and the surface ξ-potential of the NCPs were studied at different pH in aqueous media 
(PBS buffer). In acidic media (pH < 4), the protonation of the carboxylic acid, and the 
consequent reduction of ξ-potential, induces the aggregation and precipitation of the 
nanoparticles. On the other hand, the lowest particle size value is obtained at pH = 9 in which a 
high percent of carboxylic groups are deprotonated and the surface charge is highly negative 
resulting in less aggregation due to electrostatic repulsion between nanoparticles (Figure S6-S7). 
For values below pH = 4 or above pH = 9, the decomposition of the polymeric material becomes 
evident due to the complete and irreversible dissolution of the nanoparticles within a few 
seconds. In order to evaluate the colloidal and chemical stability of the nanoparticles in 
physiological conditions, dispersions of specific concentrations of the different NCPs were 
followed for 24 h and 48 h. In a typical experiment, the nanoparticles were placed inside a 
dialysis bag immersed in a PBS buffer solution at pH = 7.4 and 37 
o
C. The chemical stability of 
the NCPs was studied by FT-IR spectroscopy (Figure S8a-d) and the liberation of metal, most 
likely arising from degradation of NCPs, was quantified from outside the dialysis bag using ICP-
MS spectrometry (Figure S9a-b and Table S3). The results indicate a gradual biodegradation for 
Fe-NCP which reached the 50% metal leaching after 8 h. The Gd-NCP nanoparticles, and 
specially Mn-NCP, were less stable taking into account their decomposition rates showing 
significant leaching (50% at 5 h and 2 h for Gd-NCP and Mn-NCP, respectively). In the case of 
GdDTPA-NCP, although the chemical stability is maintained up to 6 h, the degradation turn 
evident for longer times by the successive disappearance of vibrational bands due to the chemical 
decomposition (Figure S8d). In the same way, chemical degradation is observed when UV-vis 
spectra are recorded at different times for the different systems in solution. The degradation of 
the nanoparticles and metal release are associated with the significant appearance of absorption 
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bands in the wavelength range 400-600 nm, which correspond to the absorption of soluble metal 
complexes in solution (Fe(III) at 590 nm after 24 h, Gd(III) at 450 nm after 12 h, Gd(III)DTPA 
at 550 nm after 12 h and Mn(III) at 450 nm after 4 h) (Figure 2, Table S4). Considering those 
results, a notably better stability of Fe-NCP in comparison to the other nanoparticles is 
corroborated. This result confirms what was previously expected, since the constant stability of 
metal-catechol complexes depends on the hardness character of the metal. In the case of Fe(III)-
catecholate complexes, the stability constants are extremely high compared with the Gd(III) and 
Mn(II) derivatives.
45,46
 Previous studies corroborate that Fe(III)-catechol complexes possess 
unique combination of mechanical features including high mechanical stability, fast reformation 
kinetics, and environmental sensitive mechanics.
47
 In basis of these results, the  stability of Fe-
NCP  is enough for the MRI acquisition, without accumulation within the organism avoiding 
undesirable side effects. 
3.3 Biocompatibility: cytotoxicity assays and reactive oxygen species (ROS) generation 
The biocompatibility of NCPs using in vitro viability assays on HeLa (human cervix 
carcinoma) cells was evaluated after 24 and 72 h incubation with different concentrations of 
NCPs. As shown in Figure 3a, after 24 h, iron and gadolinium-based NCPs do not show 
significant toxicity at metal concentrations up to 100 µM, meanwhile manganese-based NCPs 
showed a notable toxicity just above 10 µM. At highest concentrations (200 µM) and longest 
incubation times (72 h) only the Fe-based NCPs do not show toxicity (Figure 3b) in comparison 
with Gd- and Mn-NCP. Comparatively, the toxic effect of these two last complexes is very 
similar to the commercial gadolinium (GdDTPA) and manganese (MnDPDP) contrast agents, 
respectively (Figure S10). 
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One explanation for the toxicity detected can be attributed to the generation of reactive oxygen 
species (ROS). It is well known that many of the heavy metal ions can induce the generation of 
reactive radicals and cause cellular damage via depletion of enzyme activities through lipid 
peroxidation and reaction with nuclear proteins and DNA.
48,49
 The production of ROS induced 
by nanomaterials plays a vital role in genotoxicity and oxidative DNA damage involving 
mutagenesis, carcinogenesis and aging-related diseases.
50
 
Particularly, metal-based nanoparticles can induce toxicity due to the ionic species generated 
from nanomaterial dissolution in a suspending medium or a biological system. In this sense, 
different studies were carried out by incubation of HeLa cells for 24 h with different 
concentrations of nanoparticles from 0 to 200 μM (based on metal concentration) and using 1 
mM H2O2 as a positive control for the ROS generation (Figure 3c). All results were compared 
with the GdDTPA and MnDPDP CAs (Figure 3d). If the production of ROS by the different 
nanoconstructs is compared with their cytotoxic effect, there is a strong correlation between cell 
viability and ROS production. Thus, meanwhile Fe-NCP induces a low production of ROS in a 
dose-dependent manner even for high concentrations, the Gd-based NCPs has an increased ROS 
generation especially at concentrations higher than 100 µM. The most dramatic response 
corresponds to the Mn-NCP which presents a notable ROS production above 25 µM. Since most 
of the examples of metal-induced ROS production are related to the presence of redox-active 
metals in solution, it is interesting to mention that the appearance of a band at 450 nm during the 
degradation of Mn-NCP indicates the oxidation of Mn(II) to Mn(III).
51
 This fact would justify 
the increased toxicity observed with this system since Mn(III) results in higher oxidative 
reactivity in comparison with Mn(II) analogous.
50
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As observed in the previous studies, the chemical stability in aqueous solution of the different 
NCPs can be stated in the following order: Fe-NCP>Gd-NCP>GdDTPA-NCP>Mn-NCP that 
interestingly matches with the increasing order of cytotoxicity effect. 
3.4 Relaxivity properties of NCPs: in vitro and ex vivo MRI studies 
3.4.1 In vitro 
To evaluate the feasibility of NCPs synthesized as a platform for MRI, the longitudinal (r1) and 
transversal (r2) relaxivity values were determined by T1w and T2w images acquisition for all the 
dispersions containing the samples at different metal concentrations. For this, the NCPs were 
redispersed in PBS - agarose 1% solution at pH = 7.4 and measured (representation of R1, R2 vs 
[metal] are shown in Figure S11a-f). As shown in Figure 4a-d, all the samples display a T1w 
signal enhancement with the increase of the metal ion concentration. The obtained r1 and r2 
values are summarized in Table 2 (graphical changes on r1 and r2 are shown in Figure S12a). The 
r1 values were determined to be 5.3 ± 0.1 mM
-1
 s
-1
 for Fe-NCP, 4.4 ± 0.2 mM
-1
 s
-1
 for Gd-NCP, 
4.5 ± 0.4 mM
-1
 s
-1
 for GdDTPA-NCP, and 3.7 ± 0.1 mM
-1
 s
-1
 for Mn-NCP. The values obtained 
are comparable with the commercial GdDTPA (4.4 ± 0.7 mM
-1
 s
-1
) except for the Fe-NCP 
complex which significantly improves the referenced value. Concerning the T2w MR images, 
clear differences are found. In Fe-NCP, the T2w MR image intensity decreases (Figure 4a) with a 
concentration increase of Fe ions. Thus, the r2 value for Fe-NCP is 10.9 ± 0.3 mM
-1
 s
-1
, which is 
about twice higher than the corresponding commercial GdDTPA (r2 = 4.6 ± 0.2 mM
-1
 s
-1
). This 
increased value is ascribed to the combined effects of the local inhomogeneous magnetic fields 
created by the NCPs and the exchange of water between NCPs and the environment.
53,54
 
The MR behaviour of contrast agents relies on the relaxivity ratio (r2/r1). If the material 
behaves as a T2 contrast agent, r2/r1 ≥ 10 and as T1 contrast agent if r2/r1 < 2.
55
 Therefore, 
 22 
nanoparticles with an intermediate r2/r1 ratio can be excellent candidates as T1/T2 DMCAs. In our 
case, the in vitro phantom imaging studies are in agreement with this assumption for Fe-NCP, 
since the relaxivity ratio r2/r1 is 2.1, indicating its potential use as DMCA. The r1 value of Fe-
NCP is comparable or even higher than those found for previously reported iron-based 
coordination polymers,
56,57
 or molecular complexes,
58
 which exhibit r1 values up to 3.0 mM
-1
 s
-1
. 
Such good response is directly related to the Fe-NCP capacity to modify the relaxation times of 
the water protons in the surrounding medium when a magnetic field is applied. On the one hand, 
it has been reported that catechol-based ligands maximize second-sphere interactions with water 
molecules, and therefore to enhance T1, through hydrogen bonding with the oxygen atoms of the 
Fe–O–R linkages.59 On the other hand, the coordination polymer probably contains water 
molecules strongly coordinated to the metal sites, as well as free water molecules. These labile 
water molecules are probably in exchange with bounded water molecules, diffusing through the 
polymeric matrix.
60
 The mobility of the metal coordinated water in the first and second 
coordination spheres should induce an effect on the relaxation times of the water protons, 
resulting on the observed ratio r2/r1. 
In the case of gadolinium-based nanoparticles (Gd-NCP and GdDTPA-NCP) although they 
perform satisfactorily as T1 CAs, no significant effect as T2 CA is detected and the r2 values 
obtained (4.9 ± 0.2 mM
-1
 s
-1
 and 5.1 ± 0.3 mM
-1
 s
-1
, respectively) are comparable to the 
commercial GdDTPA complex (4.6 mM
-1
 s
-1
) resulting in r2/r1 ~ 1 ratio. The same trend is 
observed for Mn-NCP, which shows a typical behaviour of a T1 contrast agent with r2/r1 = 0.6 
ratios exhibiting value comparable to the Mn-based commercial MnDPDP CA (r1 = 3.1 ± 0.5 
mM
-1
 s
-1
, r2 = 2.3 ± 0.1 mM
-1
 s
-1
). 
3.4.2 Ex vivo 
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Before performing in vivo studies, it is necessary to select the appropriate candidate which 
produces the best relative performance in a tissue-like environment.
61,62
 Although in vitro T1 and 
T2 relaxivity times were calculated, the results obtained from them are not usually comparable in 
real tissue. Most of the in vitro strategies used to evaluate the CAs performance, are not able to 
reproduce the in vivo conditions that could modify their ability to generate contrast.
63-65
 
For these reasons, ex vivo studies were conducted essentially as reported previously.
62
 Briefly, 
each contrast NCPs was added to a PBS-BSA solution (1.25 μM in terms of metal concentration) 
and 4 μl of the resulting dispersions were intracranial administered post mortem to euthanized 
mice. The relative contrast enhancement (RCE values) was calculated for each CA. In this case, 
RCE values give information about the contrast improvement of an administered CA in 
comparison with the cerebral area without CA injected. A solution of commercial GdDTPA CA 
was used for comparison purposes (more details about protocol can be found in Experimental 
section). For statistical reasons, three ROIs were selected in T1w and T2w images, corresponding 
to CA administration points (Figure 4e-f). The T1w and T2w RCE calculated for each studied CA 
and vehicle are shown in Table 2 (graphical changes on T1 and T2 are shown in Figure S12b). Fe-
NCP and Gd-NCP presents RCE T1 comparable with the two commercial CAs GdDTPA and 
MnDPDP (with no significant differences). Mn-NCP produces poorer and non-reproducible 
results presumably due to the low stability of these nanoparticles in solution. Regarding RCE T2, 
Fe-NCP presented the best T1w/T2w result, although significance is only reached in comparison 
with commercial MnDPDP, probably due to high value dispersion. The dual potential of this CA 
is more clearly observed when the calculated ratio of RCE T1/T2 is considered. Ideally, a DMCA 
should present high absolute values for RCE T1 (signal increase) and low absolute values for 
RCE T2 (signal decrease), resulting in a high RCE T1/T2 ratio, as observed for Fe-NCP (RCE 
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T1/T2 = 7.7) (Table 2). In this case, the ex vivo studies validate the enhanced performance 
described in vitro for Fe-NCP. Additionally, the low toxicity and high chemical stability make 
this iron-based complex the best candidate for its preclinical study. 
3.5 In vivo MRI studies: tolerability, MRI imaging and biodistribution 
3.5.1 Tolerability  
Previous to in vivo assays, a tolerability study to determine the maximum safe dose for Fe-
NCP complex was done. The study was carried out following a protocol adapted and previously 
reported.
66,67
 In a typical experiment, increasing amounts of Fe-NCP (0.03 to 0.4 mmol Fe kg
-1
) 
were i.v. administered (via tail vein) to n = 3 mice with a 2-day rest period between injections. 
An additional group of 3 mice was injected with the vehicle as control (PBS with 0.5 mM Mouse 
Serum Albumin (MSA)). Mice body weight and other welfare parameters were followed for 30 
days after the last administration. In these conditions, a dose of 0.4 mmol kg
-1
of Fe-NCP proved 
safe and no body weight loss or toxicity symptoms observed during injections and for the 30-day 
period after the last administration (Figure S13). This value perfectly matches safety 
administration ranges for Fe- based nanoparticles, which can be up to 0.6 mmol kg
-1
.
68-71
 This is 
a clear added value of Fe-NCP in comparison with Gd-based contrast agents, which are widely 
used in clinical practice but are not exempt of undesired effects.
72
 
3.5.2 MRI studies 
For the in vivo CAs study, GL261 glioblastoma tumor-bearing mice were i.v. injected with 
107.1 ± 6.4 µl containing the equivalent dose of 0.4 mmol metal kg
-1
. The commercial GdDTPA 
CA was administered first, as reference for direct comparison (the complete description of the 
procedure and acquisition parameters is detailed in Experimental section). Representative T1w 
(Figure 5a,b) and T2w (Figure 5c,d) images were acquired pre- and post- CA injection. 
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In a second experiment, Fe-NCP was administered and T1w and T2w images acquired. 
Consequently, dual enhancement images were obtained through a post-processing algebra 
algorithm application (T1w/T2w, Figure 5e,f). The RCE values (Table 3) were calculated by 
manual selection of two ROIs in each MRI slice: one corresponding to the tumor region and a 
second one to the contralateral normal brain tissue (Figure 5). In this case, the RCE values give 
information about the contrast improvement before (normalized as 100%) and after CA injection. 
Maximum T1 RCE signal increase (T1max), shows remarkable differences between commercial 
GdDTPA (250.9 ± 3.1% at 6.1 ± 1.1 min) and Fe-NCP (317.4 ± 9.4% at 9.4 ± 1.1 min), which is 
notably superior (p<0.05). In T2w images, no minimum signal decrease (and accordingly no 
T2min) is observed for GdDTPA, which even show a slight signal increase (106.8 ± 2.9% at 2.6 ± 
1.1 min). However, Fe-NCP shows a notable T2w signal decrease with the minimum mean RCE 
value observed (73.7 ± 14.4%, with 26% decrease) at 5.3 ± 1.1 min. Significant differences are 
observed for RCE T1 curves of GdDTPA, Fe-NCP and vehicle (Figure S14a-b and S15). 
Additionally, the basal RCE values for Fe-NCP are completely recovered after 24 h and 30 min 
post-injection for T1 and T2, respectively. These values confirm the rapid biodegradability of Fe-
NCP and its potential as DMCA for MRI (see Figure 5f where RCE T1/T2 ratio is shown). It is 
worth noting that for Fe-NCP, the T1max is observed at 9.4 ± 1.1 min, meanwhile for the 
commercial CA the maximum is achieved at 6.1 ± 1.1 min. This difference may be related to the 
greater retention and accumulation of the nanostructured material due to the enhanced 
permeability and retention effect (EPR) of nanoparticles in tumors as described in previous 
works.
65
 In our case, the Fe-NCP nanoparticles are able to produce T1 and T2 RCE at  reasonably 
short times in the preclinical glioblastoma model (between 3.95 and 10.72 min after 
administration for maximum T1/T2 effect). This behaviour would be a clear advantage, allowing 
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the acquisition of both data types (T1w and T2w) in the same exploration, instead of performing 
two explorations with a large interlude. Thus, these nanoparticles present a clear interest for 
future studies, bearing a strong translational potential. This is not restricted to contrast 
enhancement, as they could be also used as nanocarriers for tumor-drug release and therapy in 
addition to diagnosis.
73,74
 
3.5.3 Biodistribution  
To further verify the biocompatibility studies and ex vivo/in vivo properties as MRI CAs, the 
biodistribution of Fe-NCP nanoparticles was studied. The quantification of Fe
3+
 levels within the 
different organs was determined by using ICP-MS. In Figure 6, the biodistribution of iron from 
Fe-NCP in the main organs, including the tumor, is shown. The results are based on the 
quantification of µg Fe mg
-1
 protein at 2 min and 24 h after injection of two different Fe-NCP 
doses (0.2 mmol Fe kg
-1
 and 0.4 mmol Fe kg
-1
). The experimental results indicate a dose-
dependent biodistribution. On the one hand, the very short-term biodistribution (2 min) of low 
doses of Fe-NCP show a low accumulation in heart and bladder, and notable retention in spleen. 
On the other hand, no increased levels of iron are detected in the tumor and contralateral brain 
area. However, when increasing the injected dose up to 0.4 mmol Fe kg
-1
, 2 min of circulation 
time is enough to observe the presence of Fe-NCP in the brain and tumor. After 24 h, for the low 
dose administration no increase in the concentration of iron was detected in any organ except 
spleen. Nevertheless, at high doses, notable accumulation is still observed in tumor, brain and 
bladder. At the same time, the considerable decrease in concentration observed in heart and the 
increasing concentration in bladder must be attributed to the decrease of nanoparticles in blood 
circulation and consequent excretion. The accumulation observed in the lungs, liver and kidneys 
are negligible and no significant differences were found in comparison with the basal values 
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(control wild type mice). As observed, Fe-NCP results in a minimal tissue accumulation and 
gradual degradation/excretion without bioaccumulation. These results confirm the rapid 
excretion of the nanoparticles due to the intrinsic biodegradability of the Fe-NCP complex. 
Actually, the gradual increase concentration of iron in bladder is an indicative of a gradual 
biodegradation of the Fe-NCP since the size needed to pass through the kidneys and reach the 
bladder should be smaller than 8 nm.
75
 The large uptake of the Fe-NCP observed in spleen 
indicates its important role in the nanoparticle pharmacokinetics based on their rapid clearance 
by the mononuclear phagocytic system (MPS) which is common for unmodified nanoparticles 
bigger than 40 nm.
76,77
 Although the persistence of Fe-NCP in the spleen may arise initial 
concerns, no adverse effects were detected in the 30 day-long tolerability assays described 
before. 
4. Conclusions 
Nanostructured coordination polymers (NCPs) based on Fe
3+
, Gd
3+
 and Mn
2+
 paramagnetic 
ions have been synthesized and tested as novel contrast probes with improved features in 
comparison to commercial CAs. From the different synthesized NCPs, only Fe-NCP shows 
relevant advantages in terms of: i) Chemical and colloidal stability, low cytotoxicity, and MRI 
relaxivity results as DMCA; ii) The in vivo MRI shows its T1 and T2 contrast potential, allowing 
almost simultaneous recording of positive and negative contrast images in a very short period of 
time (between 3.95 and 10.72 min after administration for maximal contrast effect); iii) This 
reduced time is a clear advantage in comparison with other DMCAs previously described, during 
which the Fe-NCP complex shows a high enough contrast activity for diagnosis and iv) The 
tolerability and biodistribution assays indicate the persistence of the nanoparticles in the tumor 
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and the gradual clearance through the kidneys denoting the biodegradability of the system. This 
work will pave the way for development of enabled biodegradable nanoparticles with T1/T2 dual-
mode MRI contrast enhancement, obtained fast and safely, and which represents a clear 
advantage in comparison with other DMCAs. Further studies will include the functionalization 
of the Fe-NCP nanoparticles surface to avoid fast elimination of the CA by the mononuclear 
phagocytic system (i.e. coating with PEG), and to increase the targeting properties for specific 
tumors. 
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Figure 1. Synthesis and morphology of the NCPs complexes. (a) Scheme for the 
synthesis of the different NCPs complexes; SEM images for (b) Fe-NCP, (c) Gd-NCP, (d) 
Mn-NCP and (e) GdDTPA-NCP. Below each SEM image, the corresponding size 
histogram for each NCP complex is shown. 
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Figure 2. Chemical stability of NCPs. The UV-vis spectra show the biodegradability through the 
time (4, 12 and 24 h) for (a) Fe-NCP, (b) Gd-NCP, (c) Mn-NCP and (d) GdDTPA-NCP. The 
arrow indicates the appearance and increase of the band related with the metal release.  
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Figure 3. The effect of the NCPs on cell viability and reactive oxygen species (ROS) generation 
in HeLa cells. Concentration-dependent cytotoxicity effects of NCPs were evaluated after (a) 24 
h and (b) 72 h of incubation. The ROS generation was evaluated for 24 h for (c) NCPs and (d) 
compared with commercial CAs. Data is shown as mean ± standard deviation. 
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Figure 4. In vitro and  ex vivo contrast effect of NCPs. Different phantoms series for each NCP 
complex at decreasing metal concentration: (a) Fe-NCP, (b) Gd-NCP, (c) Mn-NCP and (d) 
GdDTPA-NCP. The ex vivo Fe-NCP (e) T1w and (f) T2w MRI images  obtained after stereotactic 
injection of Fe-NCP, and (g) post-processing of T1w and T2w images by an algebra algorithm of 
imaging division (T1w/T2w); (h) for the ex vivo experiments all NCPs were stereotactically 
injected in brain parenchyma. The dashed circles show the selection of regions of interest (ROIs) 
for the relative contrast enhancement (RCE) calculation. Color scales show the range of pixel 
values in grayscale (for T1w and T2w weighted images) or “hot metal” color scale (for double 
enhancement images T1w/T2w), with minimum and maximum values. 
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Figure 5. Example of in vivo study of GL261 tumor bearing mice (mouse number C1210) 
administered with Fe-NCP (0.4 mmol Fe Kg
-1
). In the first row, MR images obtained before 
injection (pre-injection) are shown: (a) T1w image, (b) T2w image and (c) image obtained from an 
algebra algorithm of imaging division (T1w/T2w). In the second row, MR images after injection 
obtained at T1max (post-injection) are shown: (d) T1w image, (e) T2w image and (f) image obtained 
from an algebra algorithm of imaging division (T1w/T2w). The dashed circles show the selection 
regions of interest (ROIs) for the relative contrast enhancement (RCE) calculation. Color scales 
show the range of pixel values in grayscale (for T1w and T2w weighted images) or “hot metal” 
color scale (for double enhancement images T1w/T2w), with minimum and maximum values. 
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Figure 6. Biodistribution of Fe-NCP in mouse organs. Fe-NCP was injected into mice 
intravenously with a dosage of 0.2 or 0.4 mmol Fe kg−1 body weight. The concentration of Fe in 
different tissues was detected by ICP–MS at various time points post injection. Data is shown as 
mean ± standard deviation. 
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Table 1. Comparison of size distribution (including standard deviation values) and ξ-potential 
for NCPs in different media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NCP system SEM (nm) 
PBS PBS-BSA 
DLS (nm) ξ-Pot. (mV) DLS (nm) ξ-Pot. (mV) 
Fe-NCP 45 ± 5 97 ± 32 -31.2 56 ± 21 -19.1 
Gd-NCP 70 ± 3 121 ± 23 -27.2 73 ± 18 -14.7 
Mn-NCP 130 ± 7 189 ± 21 -15.4 151 ± 23 -2.2 
GdDTPA-NCP 75 ± 8 143 ± 17 -23.9 80 ± 15 -11.9 
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Table 2. In vitro r1 and r2 parameters and ex vivo relative contrast enhancement (RCE for T1 and 
T2) for all NCPs and comparison with the commercial CAs GdDTPA and MnDPDP. 
 
*= p<0.05 in comparison with GdDTPA, MnDPDP, Fe-NCP, Gd-NCP; ¥= p<0.05 in 
comparison with GdDTPA; €= p<0.05 in comparison with Mn-NCP; **= p<0.05 in comparison 
with MnDPDP CA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In vitro  phantoms Ex vivo 
Medium 
r1 
(mM
-1
s
-1
) 
r2 
(mM
-1
s
-1
) 
r2/r1 Medium RCE% (T1) RCE% (T2) RCE% (T1/T2) 
Fe-NCP 
PBS 
+ 
Agarose 
5.3 ± 0.1 10.9 ± 0.3*
¥
 2.1 
PBS 
+ 
BSA 
269.0 ± 28.0 44.9 ± 26.0** 7.7 ± 4.5 
Gd-NCP 4.4 ± 0.2 4.9 ± 0.2 1.1 278.6 ± 56.0 70.1 ± 25.4 4.2 ± 1.1 
Mn-NCP 3.7 ± 0.1 2.1 ± 0.1 0.6 300.9 ± 47.7 97.4 ± 14.5 3.2 ± 1.1 
GdDTPA-NCP 4.5 ± 0.4 5.1 ± 0.3 1.1 180.0 ± 64.3 78.6 ± 2.8 2.3 ± 0.8 
GdDTPA 4.4 ± 0.2 4.6 ± 0.7 1.1 253.1 ± 32.8 74.9 ± 17.6 3.6 ± 1.4 
MnDPDP 3.1 ± 0.5 2.3 ± 0.1 0.7 300.9 ± 47.7 97.4 ± 14.5 3.2 ± 1.1 
Vehicle - - - 118.6 ± 8.8 122.9 ± 11.5*
¥
 0.97 ± 0.07*
¥€
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Table 3. In vivo relative contrast enhancement (RCE) for the Fe-NCP complex and the 
commercial contrast agent GdDTPA. 
 
a
The 100% RCE is  the normalized reference value corresponding to the pre-injection MRI. 
*= p<0.05 in comparison with GdDTPA RCE T1w pre-injection; **= p<0.05 in comparison 
with GdDTPA RCE T2w pre-injection; ***= p<0.05 in comparison with Fe-NCP T1w pre-
injection; £= p<0.05 in comparison with Fe-NCP T2w pre-injection; ¥= p<0.05 in comparison 
with GdDTPA at T1max; € = p<0.05 in comparison with GdDTPA at T2min. If the obtained values 
ranged >95 to <105% (i.e. less than 5% variation respect to pre-injection), they were considered 
as “no change” respect to pre-injection.  
 
 
 
 
 
 
ASSOCIATED CONTENT 
Supporting Information.  
 
In vivo relative contrast enhancement (RCE %) 
T1w (increase)
a 
T2w (decrease)
a 
T1max 2 h 24 h T2min 2 h 24 h 
Fe-NCP 
317.4 ± 15.4 
*** ¥ 
123.5 ± 4.6 
*** 
88.3 ± 6.7 
*** 
73.7 ± 14.4 
£,€ 
103.1 ± 9.9 
 
79.4 ± 4.2 
£ 
GdDTPA 
250.9 ± 3.1 
* 
111.8 ± 2.7 
* 
101.0 ± 4.0 
106.8 ± 2.9 
** 
102.1 ± 7.0 
 
102.3 ± 7.3 
Vehicle 
PBS-MSA 
101.2 ± 1.8 
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Figures S1 to S15 and Tables S1 to S4 are available free of charge on the ACS Publications 
website. Physicochemical characterization (DLS, FT-IR, XPS, Mössbauer, EA, ICP-MS,PXRD). 
Colloidal stability (DLS). Chemical stability (FT-IR, UV-vis, ICP-MS). In vitro cell viability. In 
vitro MRI. In vivo MRI. 
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